239 related articles for article (PubMed ID: 2614190)
21. Generation of activated killer-like cells by OK-432-mediated production of interleukin 1, interleukin 2, and interferon-gamma in vitro.
Ujiie T
Jpn J Exp Med; 1987 Dec; 57(6):333-8. PubMed ID: 3131563
[TBL] [Abstract][Full Text] [Related]
22. OK-432 stimulates primary production and activity of murine natural killer cells.
Pollack SB
Nat Immun Cell Growth Regul; 1987; 6(5):224-36. PubMed ID: 3444437
[TBL] [Abstract][Full Text] [Related]
23. [Experimental and clinical study of adoptive immunotherapy combined with preadministration of OK-432: a method to augment the therapeutic effect].
Kan N; Okino T; Nakanishi M; Sato K; Mise K; Teramura Y; Yamasaki S; Hori T; Ohgaki K; Tobe T
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1455-61. PubMed ID: 2786379
[TBL] [Abstract][Full Text] [Related]
24. [Role of the spleen in OK-432 immunotherapy and characterization of effector cells].
Yamagishi H; Naito K; Maeda Y; Kobayashi M; Kurioka H; Fujimori C; Tanaka T; Hashimoto I
Gan To Kagaku Ryoho; 1983 Jul; 10(7):1670-8. PubMed ID: 6870309
[TBL] [Abstract][Full Text] [Related]
25. Enhanced generation of OK-432-induced killer cells by interleukin 2.
Ujiie T
Jpn J Exp Med; 1987 Jun; 57(3):183-8. PubMed ID: 3500332
[TBL] [Abstract][Full Text] [Related]
26. Monoclonal antibody to a human salivary gland adenocarcinoma cell line: augmentation of antibody-dependent cell-mediated cytotoxicity activity by streptococcal preparation OK-432 in human salivary gland adenocarcinoma-bearing nude mice given the antibody.
Kaji R; Yoshida H; Yanagawa T; Sato M
J Biol Response Mod; 1989 Oct; 8(5):488-500. PubMed ID: 2552025
[TBL] [Abstract][Full Text] [Related]
27. IL-15 mediates anti-tumor effects after cyclophosphamide injection of tumor-bearing mice and enhances adoptive immunotherapy: the potential role of NK cell subpopulations.
Evans R; Fuller JA; Christianson G; Krupke DM; Troutt AB
Cell Immunol; 1997 Jul; 179(1):66-73. PubMed ID: 9259773
[TBL] [Abstract][Full Text] [Related]
28. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
[TBL] [Abstract][Full Text] [Related]
29. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
30. Augmentation of the antimetastatic effect of anticoagulant drugs by immunostimulation in mice.
Gorelik E
Cancer Res; 1987 Feb; 47(3):809-15. PubMed ID: 3802083
[TBL] [Abstract][Full Text] [Related]
31. Augmentation of mouse natural killer cell activity by a streptococcal preparation, OK-432.
Oshimi K; Kano S; Takaku F; Okumura K
J Natl Cancer Inst; 1980 Dec; 65(6):1265-9. PubMed ID: 7001124
[TBL] [Abstract][Full Text] [Related]
32. Killing of rat adenocarcinoma 13762 in situ by adoptive transfer of CD4+ anti-tumor T cells requires tumor expression of cell surface MHC class II molecules.
Frey AB; Cestari S
Cell Immunol; 1997 May; 178(1):79-90. PubMed ID: 9184701
[TBL] [Abstract][Full Text] [Related]
33. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression.
Huang H; Li F; Gordon JR; Xiang J
Cancer Res; 2002 Apr; 62(7):2043-51. PubMed ID: 11929823
[TBL] [Abstract][Full Text] [Related]
34. Combined immunogene therapy of IL-6 and IL-15 enhances anti-tumor activity through augmented NK cytotoxicity.
Lin CY; Chuang TF; Liao KW; Huang YJ; Pai CC; Chu RM
Cancer Lett; 2008 Dec; 272(2):285-95. PubMed ID: 18760876
[TBL] [Abstract][Full Text] [Related]
35. Antitumor activity of a Streptococcus pyogenes preparation (OK-432). I. Sequential effector mechanisms following a single OK-432 injection in F344 rats leading to the rejection of syngeneic MADB106 tumor cells.
Fukui H; Reynolds CW
J Natl Cancer Inst; 1987 Nov; 79(5):1011-7. PubMed ID: 3479632
[TBL] [Abstract][Full Text] [Related]
36. CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes.
Martinotti A; Stoppacciaro A; Vagliani M; Melani C; Spreafico F; Wysocka M; Parmiani G; Trinchieri G; Colombo MP
Eur J Immunol; 1995 Jan; 25(1):137-46. PubMed ID: 7843224
[TBL] [Abstract][Full Text] [Related]
37. Combined IFN-gamma-endostatin gene therapy and radiotherapy attenuates primary breast tumor growth and lung metastases via enhanced CTL and NK cell activation and attenuated tumor angiogenesis in a murine model.
Liu LL; Smith MJ; Sun BS; Wang GJ; Redmond HP; Wang JH
Ann Surg Oncol; 2009 May; 16(5):1403-11. PubMed ID: 19263173
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms of in vivo generation of cytotoxic effector cells against tumor in tumor-bearing mice.
Fuyama S; Yamamoto H; Fujii Y; Arai S
Cancer Res; 1986 Nov; 46(11):5548-52. PubMed ID: 2428480
[TBL] [Abstract][Full Text] [Related]
39. Cell regulatory and immunorestorative activity of picibanil (OK432).
Chirigos MA; Saito T; Talmadge JE; Budzynski W; Gruys E
Cancer Detect Prev Suppl; 1987; 1():317-28. PubMed ID: 3480058
[TBL] [Abstract][Full Text] [Related]
40. Antitumor effects of recombinant human prolactin in human adenocarcinoma-bearing SCID mice with human NK cell xenograft.
Zhang J; Sun R; Wei H; Tian Z
Int Immunopharmacol; 2005 Feb; 5(2):417-25. PubMed ID: 15652770
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
